1H, was 0.77 m. == Figure 1. significant fraction of Eps8 bound to (11.9 5.1%) and was incorporated into (5.3 6.5%) lysosomes. Additionally, Eps8 binding to lysosomes was competed by other known CMA-substrates. Fluorescence recovery after photobleaching revealed that Eps8 recruitment to the lysosomal membrane was highly dynamic. Collectively, these results indicate that Eps8 in certain human cancer cells specifically localizes to lysosomes, and is directed to CMA. These results open a new field for the investigation of how Eps8 is regulated and contributes to tumor promotion in human cancers Keywords:Eps8, lysosome, autophagy, pancreatic cancer, actin, lamp == Introduction == The epidermal growth factor receptor pathway substrate 8 (Eps8) is a 97 kDa protein that was originally indentified as a substrate for the kinase activity of the epidermal growth factor receptor (EGFR). Early results demonstrated that Eps8 increased epidermal growth factor (EGF) responsiveness, thus contributed to malignant transformation in tumor cells [1,2]. There is now growing evidence that Eps8 plays an important role in promotion of various solid malignancies, including colon, squamous cell, thyroid and cervical cancer [37]. We recently reported that Eps8 expression is enhanced in metastatic pancreatic cancer cells when compared to cells from the primary tumor [8]. Moreover, high Eps8 expression in metastatic cells was associated with increased cell motility and accumulation of Eps8 at actin dynamic sites, e.g. the leading edge of the cells. The Eps8 molecule controls actin remodeling through multiple interactions. The C-terminal Evobrutinib effector region directly binds F-actin and caps actin barbed ends [9]. In addition, Eps8 participates in the activation of the small GTPase Rac in a tri-protein complex with Abi1 and Sos1, and synergizes with IRSp53 to bundle actin filaments [10]. A number of recent evidence indicates that actin dynamics and endocytic machineries Evobrutinib are intimately related. This notion appears to apply also in the case of Eps8. Rac-signaling through Eps8 can be hampered by binding of RN-tre, a GTPase activating protein (GAP) for Rab5, to the src homology-3 (SH3) domain of Eps8, leading to disruption of the Eps8-Abi1-Sos-1 complex and to Evobrutinib the deactivation of Rab5, which in turns regulates the internalization of EGFR [11]. Intriguingly, Rab5-dependent endocytosis and early endosome trafficking have recently been shown to be required for Rac-mediated, spatially restricted actin remodeling at the cell periphery [12]. Within this context, Eps8 has all the features to predict that it might be an important regulatory element mediating the cross talk between membrane and actin dynamics, which utlimately is required to generate propulsive force at the leading cell edge upon motogenic stimuli. However, whether Eps8 directly participates in membrane internalization and/or endomembrane trafficking remains unclear. Since there is little known about the degradation of Eps8 [13], it might be possible that the regulatory function of Eps8 is controlled through its expression levels. Chaperone-mediated autophagy (CMA) is a lysosomal for the selective degradation of cytosolic proteins [14]. Unlike other forms of autophagy, CMA is a cellular process that mediates the direct translocation of individual proteins across the Evobrutinib lysosome membrane for their degradation in the lysosome [15]. CMA activity decreases with age and has shown to be altered in different human pathologies. Malfunctioning autophagy has been closely linked to oncogenic signaling [16]. Here, we investigate a novel association of Eps8 to the lysosomal compartment in human cancer cells and describe its degradation through CMA. == Material and Methods == == Expression vectors, antibodies, reagents and siRNA == Vectors encoding Evobrutinib for GFP fusion proteins were engineered in the pEGFP C1 plasmid (Clontech Laboratories, Inc.) by cloning the appropriate fragments, obtained by recombinant PCR, in frame with the GFP moiety as described recently [17]. All constructs were sequence verified. Details are available upon request. Cell Rabbit Polyclonal to OR5M3 transfection was performed with Lipofectamine 2000 (Invitrogen, Eugene, OR) according to the manufacturers instructions. The antibodies used were: mouse monoclonal anti-Eps8 (Transduction Laboratories, Lexington, KY), rabbit polyclonal anti-Eps8 [1], mouse anti-EEA1 (clone 14, BD Biosciences), rabbit anti-EGFR.